Neonatal Research Institute
Clinical Trial: Treatment of Ductus Arteriosus
Clinical trial: Patent Ductus Arteriosus: Trial of early treatment versus conservative treatment of the patent ductus arteriosus (PDA)
Primary investigator: Dr. Ron Clyman
What is the ductus arteriosus?
Before birth, there is no need for a baby to breathe. The baby gets oxygen from the placenta. A small blood vessel in the baby's heart allows blood to bypass (skip) the lungs and go straight to the rest of the body. This blood vessel is called the ductus arteriosus. At birth, a baby starts to breathe. Oxygen now comes from the baby's own lungs. The ductus arteriosus is no longer needed. It usually closes within days of birth.
What is PDA?
In some babies, the ductus arteriosus does not close soon after birth. This is called patent ductus arteriosus, or PDA. In the case of PDA, patent means "open." In some babies, PDA does not cause any problems. The size of the vessel is important. However, larger PDAs allow more blood to go back to the lungs instead of out to the rest of the body. This can increase blood pressure in the lungs. This also makes the baby's heart work harder.
How can we treat PDAs?
Treatment of PDAs can involve medicines that have side effects, which can be harmful to premature infants. However, some recent studies suggest that giving acetaminophen (Omfirmev) can be gentler on the babies without harmful side effects.
Our hypothesis is that early treatment of a moderate size PDA with acetaminophen (Omfirmev) will:
- Decrease the need for surgical repair
- Improve long-term neurodevelopment
- Reduce the length of hospital stay
To learn more about the NICU at Sharp Mary Birch, visit Neonatal Intensive Care Unit. For more information about the NRI or to learn more about our clinical trials, send us an email or call 858-939-4112.